The global viral clearance services market was valued at USD 389.7 million in 2020 and is expected to grow at a CAGR of 19.8% over the forecast period. The global viral clearance services market is being driven by a strong pharmaceutical product pipeline and increased government support for the pharmaceutical and biotechnology industries.
Adroit Market Research report on global viral clearance services market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities, and challenges. The market has been studied for the period 2018 to 2028, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market competition with Porter's five forces analysis and company positioning based on their product portfolio, geographic footprint, strategic initiatives, and overall revenue. Prominent players operating in the global viral clearance services market have been studied in detail.
North America currently holds the largest share in viral clearance services market owing to the presence of significant number of major players across the region along with growing investments by the established firms. Furthermore, Asia Pacific is going to record growth at a faster pace on account of rising pharmaceutical and biotech sector across emerging economies such as China and India.
The prominent players operating in global viral clearance services market includes Charles River Laboratories, Labor Dr. Merk & Kollegen GmbH, Texcell, Merck KGaA, WuXi AppTec, Sartorius AG, Bioscience Laboratories, Eurofins Scientific, Syngene International Limited, Covance among other prominent players.
Key segments of the global viral clearance services market
Method Overview, 2018-2028 (USD Million)
- Viral Removal
- Viral Inactivation
Application Overview, 2018-2028 (USD Million)
- Recombinant Proteins
- Tissue and Blood Derived Products
- Vaccines
- Others
End-User Overview, 2018-2028 (USD Million)
- Biopharmaceuticals
- Contract Research Organizations
- Academic Research Institutes
Regional Overview, 2018-2028 (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- South America
- Brazil
- Mexico
- Rest of South America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East and Africa